CNSPCNS Pharmaceuticals, Inc.
Health Care
Net Income (Loss) Attributable to Parent revised up 99.9% for FY 2023
Net Income (Loss) Attributable to Parent·FY 2023
Major restatement-$18.9K▲ 99.9%
was-$18.9M
Revised up.
Verify against SEC filingsShow
As reported-$18.9M
Accepted 2024-04-010001683168-24-002032
Restated-$18.9K
Accepted 2026-08-210001683168-26-006660
NetIncome · reported 3 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time CNSP — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.